HomeMedical SpecialtiesCardiologyBringing ground-breaking innovations to the bedside

Bringing ground-breaking innovations to the bedside

Published on

When Health Canada officially approved the revolutionary, catheter-based, MitraClip therapy last April, interventional cardiologists and surgeons at the University of Ottawa Heart Institute knew they had been pioneering an innovative and novel procedure.

Now providing physicians in Canada with a breakthrough treatment option that can significantly improve symptoms, disease progression and quality of life for certain patients with a heart condition called mitral regurgitation (MR), the MitraClip device has been approved for people with degenerative MR who are too high risk for mitral valve surgery based on evaluation by a team of cardiologists and surgeons at the Ottawa Heart Institute.

MORE: THE DIABETES EPIDEMIC

“This extraordinary achievement in interventional cardiology would not be possible without the exceptional teamwork our highly specialized experts have demonstrated over the last years. Our ability to continuously develop our innovative approach is truly the product of our team’s unique dedication and limitless ambition,” said Dr. Marino Labinaz, Cardiologist and the Director of both the Cardiac Catheterization Laboratory and the Cardiac Fellowship Program at the University of Ottawa Heart Institute.

Degenerative MR is a type of mitral regurgitation caused by an anatomic defect of the mitral valve of the heart. Treatment with the MitraClip device can be effective in reducing the symptoms associated with severe mitral regurgitation, such as shortness of breath and fatigue, which may help people lead a more active lifestyle.

Mitral regurgitation is a common condition, affecting an estimated one in 10 people aged 75 and above. Severe mitral regurgitation can be a debilitating, progressive and life-threatening disease in which a leaky mitral valve causes a backward flow of blood in the heart. The condition can raise the risk of irregular heartbeats, stroke, and heart failure. Open heart mitral valve surgery is the standard-of-care treatment, but many patients are too high risk for an invasive procedure. Medications for the condition are limited to reducing symptoms and do not have the ability to stop the progression of the disease.

MORE: SOUTHLAKE IMPLANTS WORLDS SMALLEST HEART MONITOR IN ADULT PATIENT

“Multiple trials, published reports, and registries of patients treated with the MitraClip device consistently demonstrate a positive safety profile, a reduction in mitral regurgitation, improvements in symptoms, and a reduction in hospitalizations for heart failure,” said Dr. Thierry Mesana, cardiac surgeon and the President and CEO of the University of Ottawa Heart Institute.

Developed by Abbott, the MitraClip repairs the mitral valve without the need for an invasive surgical procedure. The device is delivered to the heart through the femoral vein, a blood vessel in the leg, and once the device is implanted, allows the heart to pump blood more efficiently, thereby relieving symptoms and improving quality of life. Patients undergoing MitraClip treatment typically experience short recovery times and short hospital stays of two to three days.

Latest articles

An ER doctor’s experience with long COVID – “My symptoms seemed endless”

On April 2022, another COVID wave was sweeping Toronto. It was the sixth since...

Tackling the issue of unused medication waste

When patients and programs don’t use all the medication that is prescribed, it is...

Obesity a risk factor for stillbirth, especially at term

Obesity is a risk factor for stillbirth, and the risk increases as pregnancy advances...

Prolonged cough? In most cases, patience is the treatment

Coughing after a respiratory infection is common and, in most cases, will resolve with...

More like this

Prolonged cough? In most cases, patience is the treatment

Coughing after a respiratory infection is common and, in most cases, will resolve with...

A New Era in Heart Failure Management: The Promise of Digital Therapeutics

Heart failure is one of the fastest growing cardiovascular conditions in the world that...

Funding to take LHSC developed technology global

On average it takes five to seven years to diagnose a rare disease. But,...

Milk and Colorectal Cancer: what does the research say?

Colorectal cancer is the fourth most common cancer in Canada and is more common...

Surgical guidance with AI

Researchers at UHN’s Toronto General Hospital Research Institute (TGHRI) have utilized artificial intelligence (AI)...

Report outlines public health response to COVID-19 outbreaks at mink farms

A report co-authored by Fraser Health Medical Health Officer Dr. Emily Newhouse and published...